Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...
Medpage Today on MSN4d
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney DiseaseThe dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
A team of researchers, led by one of Indian origin, has found that a drug recently approved by the US Food and Drug Administration (FDA) to treat type 2 diabetes can also reduce heart attacks and ...
News Medical on MSN4d
Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial showsSotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular ...
A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...
Valentine’s Day has come and gone, but it’s never too late to focus on your heart health. A groundbreaking new study suggests that sotagliflozin, a drug recently approved to treat type 2 diabetes and ...
The results showed that people who took sotagliflozin had a 23% lower risk of heart attacks, strokes, and death from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback